105 related articles for article (PubMed ID: 29431693)
1. An Antigen-Free, Plasmacytoid Dendritic Cell-Targeting Immunotherapy To Bolster Memory CD8
Masuta Y; Yamamoto T; Natsume-Kitatani Y; Kanuma T; Moriishi E; Kobiyama K; Mizuguchi K; Yasutomi Y; Ishii KJ
J Immunol; 2018 Mar; 200(6):2067-2075. PubMed ID: 29431693
[TBL] [Abstract][Full Text] [Related]
2. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.
Kobiyama K; Aoshi T; Narita H; Kuroda E; Hayashi M; Tetsutani K; Koyama S; Mochizuki S; Sakurai K; Katakai Y; Yasutomi Y; Saijo S; Iwakura Y; Akira S; Coban C; Ishii KJ
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3086-91. PubMed ID: 24516163
[TBL] [Abstract][Full Text] [Related]
3. Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.
Kobiyama K; Temizoz B; Kanuma T; Ozasa K; Momota M; Yamamoto T; Aoshi T; Kuroda E; Ishii KJ
Eur J Immunol; 2016 May; 46(5):1142-51. PubMed ID: 26786557
[TBL] [Abstract][Full Text] [Related]
4. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
Kitahata Y; Kanuma T; Hayashi M; Kobayashi N; Ozasa K; Kusakabe T; Temizoz B; Kuroda E; Yamaue H; Coban C; Yamamoto T; Kobiyama K; Aoshi T; Ishii KJ
Oncotarget; 2016 Aug; 7(31):48860-48869. PubMed ID: 27384490
[TBL] [Abstract][Full Text] [Related]
5. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
Ito H; Ando T; Nakamura M; Ishida H; Kanbe A; Kobiyama K; Yamamoto T; Ishii KJ; Hara A; Seishima M; Ishikawa T
J Viral Hepat; 2017 Feb; 24(2):155-162. PubMed ID: 27807909
[TBL] [Abstract][Full Text] [Related]
6. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
7. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.
Yamamoto T; Masuta Y; Momota M; Kanekiyo M; Kanuma T; Takahama S; Moriishi E; Yasutomi Y; Saito T; Graham BS; Takahashi Y; Ishii KJ
Int Immunol; 2019 Feb; 31(2):81-90. PubMed ID: 30535055
[TBL] [Abstract][Full Text] [Related]
8. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.
Goold HD; Escors D; Conlan TJ; Chakraverty R; Bennett CL
J Immunol; 2011 Apr; 186(8):4565-72. PubMed ID: 21389256
[TBL] [Abstract][Full Text] [Related]
9. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
10. In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy.
Okada H; Takahashi K; Yaku H; Kobiyama K; Iwaisako K; Zhao X; Shiokawa M; Uza N; Kodama Y; Ishii KJ; Seno H
Sci Rep; 2022 Feb; 12(1):2132. PubMed ID: 35136110
[TBL] [Abstract][Full Text] [Related]
11. CD44high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production.
Wong KL; Tang LF; Lew FC; Wong HS; Chua YL; MacAry PA; Kemeny DM
J Immunol; 2009 Jul; 183(1):41-50. PubMed ID: 19535645
[TBL] [Abstract][Full Text] [Related]
12. Antigen-dependent and -independent contributions to primary memory CD8 T cell activation and protection following infection.
Martin MD; Badovinac VP
Sci Rep; 2015 Dec; 5():18022. PubMed ID: 26658291
[TBL] [Abstract][Full Text] [Related]
13. IL-10 promotes homeostatic proliferation of human CD8(+) memory T cells and, when produced by CD1c(+) DCs, shapes naive CD8(+) T-cell priming.
Nizzoli G; Larghi P; Paroni M; Crosti MC; Moro M; Neddermann P; Caprioli F; Pagani M; De Francesco R; Abrignani S; Geginat J
Eur J Immunol; 2016 Jul; 46(7):1622-32. PubMed ID: 27129615
[TBL] [Abstract][Full Text] [Related]
14. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
15. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
16. A bacterial flagellin in combination with proinflammatory cytokines activates human monocyte-derived dendritic cells to generate cytotoxic T lymphocytes having increased homing signals to cancer.
Hong CY; Kim SY; Lee HJ; Lee SE; Lim SC; Rhee JH; Lee JJ
J Immunother; 2014 Jan; 37(1):16-25. PubMed ID: 24316552
[TBL] [Abstract][Full Text] [Related]
17. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
[TBL] [Abstract][Full Text] [Related]
18. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
19. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.
Farrand KJ; Dickgreber N; Stoitzner P; Ronchese F; Petersen TR; Hermans IF
J Immunol; 2009 Dec; 183(12):7732-42. PubMed ID: 19923446
[TBL] [Abstract][Full Text] [Related]
20. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
